Phaseline

Targets › CFB

CFB (Complement factor B): drug programs, companies and trials

5 programs from 5 companies in 18 trials: 10 Phase 3, 6 Phase 2, 2 Phase 1; Hematology, Ophthalmology, Genitourinary; next expected readout Dec 2026.

Precursor of the catalytic component of the C3 and C5 convertase complexes of the alternative pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. The alternative complement pathway acts as an amplification loop that enhances other complement pathways (classical, lectin and GZMK) by promoting formation…. (UniProt, P00751)

Open in Phaseline: the race on CFB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisIptacopan
Complement factor B inhibitor
CFBPhase 3C3G; Generalized Myasthenia Gravis; Paroxysmal Nocturnal Hemoglobinuria; Atypical Hemolytic Uremic Syndrome …Dec 2026
Suzhou Sanegene BioSGB-9768
Factor B (CFB) inhibitor
CFBPhase 2IgA Nephropathy (IgAN)Dec 2026
Nanjing Chia-tai Tianqing PharmaceuticalNTQ5082
Factor B (CFB) inhibitor
CFBPhase 2Paroxysmal Nocturnal HemoglobinuriaJul 2027
Kriya TherapeuticsVV-14295 (KRIYA-825)
Adeno-associated virus (AAV) vector delivering a soluble fms-like tyrosine kinase-1 (sFlt-
CFBPhase 1Geographic Atrophy Secondary to Age-related Macular DegenerationDec 2027
Regeneron PharmaceuticalsALN-CFB
small interfering RNA (siRNA) targeting Complement Factor B
CFBPhase 1Paroxysmal Nocturnal Hemoglobinuria (PNH)Nov 2029

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH) (2) Paroxysmal Nocturnal Hemoglobinuria (2) Atypical Hemolytic Uremic Syndrome (2) Geographic Atrophy Secondary to Age-related Macular Degeneration (1) C3G (1) Generalized Myasthenia Gravis (1) IC-MPGN (1) Primary Immunoglobulin A Nephropathy (IgAN) (1) Primary IgA Nephropathy (1) C3 Glomerulopathy (1) Lupus Nephritis (1) Age-Related Macular Degeneration (1)

Modalities

small molecule (4), other (1)

Companies

Regeneron Pharmaceuticals (1) Kriya Therapeutics (1) Novartis (1) Suzhou Sanegene Bio (1) Nanjing Chia-tai Tianqing Pharmaceutical (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.